ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02845856
Recruitment Status : Recruiting
First Posted : July 27, 2016
Last Update Posted : July 27, 2016
Sponsor:
Collaborator:
Shenzhen Hank Bioengineering Institute
Information provided by (Responsible Party):
Fuda Cancer Hospital, Guangzhou

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2017
  Estimated Study Completion Date : July 2019